RESAPP HEALTH LIMITED – VOLUNTARY SUSPENSION EXTENSION
Further to the request on 2 June 2022 for the securities of ResApp Health Limited (“Company” to be placed in voluntary suspension, the Company hereby requests that the voluntary suspension be extended pending the release of an announcement by the Company providing an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in the Company by way of a Scheme of Arrangement.
RAP Price at posting:
11.0¢ Sentiment: Buy Disclosure: Held
to be placed in voluntary suspension, the Company hereby requests that the voluntary suspension be extended pending the release of an announcement by the Company providing an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in the Company by way of a Scheme of Arrangement.
